Skip to main content

Table 4 Incidence of gastrointestinal adverse events occurring in ≥ 10% of patients during the two year treatment period

From: Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]

  Percentage of patients with event
  Clodronate (n = 530) Placebo (n = 539)
Nausea 27.0 29.8
Diarrhoea1 19.9 10.0
Dyspepsia 15.6 13.3
Vomiting 14.7 13.1
Abdominal pain 13.6 10.5
Constipation 12.5 12.2
Stomatitis 8.4 10.2
  1. 1P < 0.05 versus placebo.